MiraVista Diagnostics, a developer of diagnostic tests for fungal diseases, has unveiled plans to upgrade its Indianapolis headquarters.
The company, which processes over 100,000 fungal infection tests annually, will invest more than $5.3 million to expand and equip its headquarters at 4705 Decatur Blvd., doubling the size of its current facility to 48,000 sq. ft.
MiraVista says that it will grow its on-site infectious disease diagnostic laboratory to diversify its testing services to other diseases and scale up the R&D and production of in-vitro diagnostic devices.
“The city of Indianapolis and Decatur Township have been great places to grow and provide diagnostic testing services both nationally and globally,” MiraVista founder Lawrence Joseph Wheat said in a press statement. “As the second largest exporter of life sciences products in the U.S., only behind California, it’s been a tremendous source of pride to contribute to Indiana’s robust research and life sciences industries. The state and city continue to demonstrate a strong commitment to attracting and keeping businesses and talent here in Indiana.”
MiraVista expects to complete the project by December 2019.
